TCGA-49-4494-01A-01R-1206-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- CHOLESTEROL_HOMEOSTASIS+0.500
- INTERFERON_GAMMA_RESPONSE+0.450
- OXIDATIVE_PHOSPHORYLATION+0.390
- MTORC1_SIGNALING+0.370
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
- GLYCOLYSIS+0.360
- ADIPOGENESIS+0.350
- COAGULATION+0.310
- ESTROGEN_RESPONSE_LATE+0.310
Top 10 suppressed
- MITOTIC_SPINDLE-0.420
- HEDGEHOG_SIGNALING-0.360
- WNT_BETA_CATENIN_SIGNALING-0.350
- UV_RESPONSE_DN-0.300
- G2M_CHECKPOINT-0.190
- MYOGENESIS-0.120
- TGF_BETA_SIGNALING-0.050
- SPERMATOGENESIS-0.030
- APICAL_SURFACE-0.020
- APICAL_JUNCTION-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 551ADCCD-D116-43D8-AABC-E7E111D79E70 | — | — | 0.910 |
| 2 | ff02e85e-2f87-4832-aaea-3322db33c57a | — | — | 0.898 |
| 3 | TCGA-38-4632-01A-01R-1755-07 | — | cohortA1 | 0.892 |
| 4 | bc895549-854b-484f-8a6d-9e5152829bcb | — | — | 0.887 |
| 5 | SRR33532822 | — | C | 0.883 |
| 6 | TCGA-33-4589-01A-01R-1443-07 | — | cohortSQ1 | 0.876 |
| 7 | 31550B35-DA39-4294-8368-811A412B2E3A | — | — | 0.875 |
| 8 | TCGA-05-4418-01A-01R-1206-07 | — | cohortA4 | 0.872 |
| 9 | TCGA-BA-5152-01A-02R-1873-07 | — | — | 0.870 |
| 10 | TCGA-05-5425-01A-02R-1628-07 | — | cohortA4 | 0.863 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.500 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.450 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.390 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.360 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.290 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| APOPTOSIS | 0.260 | Idelalisib | — uncovered |
| PEROXISOME | 0.260 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.240 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.230 | Cobimetinib | — uncovered |